Tonix up after peer reviewed data for pain therapy and new data for mpox vaccine

5 hours ago 1

Healthcare
On the Move

Definition of the word Fibromyalgia in a dictionary

Tonix Pharmaceuticals (NASDAQ:TNXP) added ~10% on Thursday after the company announced peer-reviewed data from a Phase 3 trial for its pain therapy candidate TNX-102 SL, and new findings related to TNX-801 its vaccine candidate for mpox and smallpox.

Issuing a

Recommended For You

More Trending News

Read Entire Article

Tonix up after peer reviewed data for pain therapy and new data for mpox vaccine

Recommended For You

More Trending News

Related

Merck Animal Health gets FDA nod for Bravecto Quantum

Lockheed Martin awarded $197.48M U.S. Navy contract modifica...

Century Therapeutics files $200M mixed shelf offering

Alpine Banks of Colorado declares $0.21 dividend

AptarGroup declares $0.45 dividend

Boyd Gaming to sell equity interest in FanDuel for $1.76B

Avient declares $0.27 dividend

Federal Agricultural Mortgage announces CFO resignation

abrdn World Healthcare Fund declares $0.1167 dividend

LNG Canada start-up not yet lifting natural gas prices - Reu...

abrdn Global Premier Properties Fund declares $0.04 dividend...

Lubricant maker WD-40 reports mixed third quarter, updates F...

CBRE Global Real Estate Income Fund declares $0.06 dividend

Bitcoin sets new record, topping $!!3K

Alpha Teknova files $225M mixed securities shelf

Civista Bancshares expands Northeast Ohio presence with Farm...

Levi Strauss & Co beats top- and bottom-line expectations, r...

Toll Brothers names next CFO

Ryder raises quarterly dividend by 12.3% to $0.91/share

First Trust Income Opportunities ETF declares $0.135 dividen...

Trending

Popular

TechCrunch Mobility: The state of EV sales and Rivian secure...

Castelion raises $350M Series B to scale hypersonic missile ...